Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mutated p53 protein, resulting from mutations in the TP53 gene, is a dysfunctional form of the p53 tumor suppressor. These mutations commonly occur within the DNA-binding domain, leading to loss-of-function, dominant-negative, or gain-of-function effects. Mutant p53 impairs cell cycle checkpoints and apoptosis, promoting cancer development. Certain mutant forms exhibit oncogenic activities. Therapeutic strategies aim to restore wild-type function or eliminate harmful mutant activities.
Restoration of wild-type p53 function, Inhibition of mutant p53 function, Targeted degradation of mutant p53
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor Protein p53 (Mutated) (p53 (Mutated)).